Q3 Earnings Roundup: Cardinal Health (NYSE:CAH) And The Rest Of The Healthcare Providers & Services Segment

Stock Story

Guardant Health

-7.34%

Brookdale Senior Living

Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health and its peers.

The healthcare providers and services sector, from insurers to hospitals, benefits from consistent demand, generating stable revenue through premiums and patient services. However, it faces challenges from high operational and labor costs, reimbursement pressures that squeeze margins, and regulatory uncertainty. Looking ahead, an aging population with more chronic diseases and a shift toward value-based care create tailwinds. Digitization via telehealth, data analytics, and personalized medicine offers new revenue streams. Nonetheless, headwinds persist, including clinical labor shortages, ongoing reimbursement cuts, and regulatory scrutiny over pricing and quality.

The 40 healthcare providers & services stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 2.3% while next quarter’s revenue guidance was 0.6% below.

In light of this news, share prices of the companies have held steady as they are up 1.8% on average since the latest earnings results.

Cardinal Health

Operating as a critical link in the healthcare supply chain since 1979, Cardinal Health distributes pharmaceuticals and manufactures medical products for hospitals, pharmacies, and healthcare providers across the global healthcare supply chain.

Cardinal Health reported revenues of $64.01 billion, up 22.4% year on year. This print exceeded analysts’ expectations by 7.8%. Overall, it was an exceptional quarter for the company with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

"We are pleased with our strong broad-based operational and financial performance to begin fiscal 2026," said Jason Hollar, CEO of Cardinal Health.

Interestingly, the stock is up 20.7% since reporting and currently trades at $198.49.

We think Cardinal Health is a good business, but is it a buy today? Read our full report here, it’s free for active Edge members.

Best Q3: Guardant Health

Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.

Guardant Health reported revenues of $265.2 million, up 38.5% year on year, outperforming analysts’ expectations by 12.6%. The business had an incredible quarter with an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Guardant Health scored the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 33.8% since reporting. It currently trades at $96.69.

Slowest Q3: Brookdale

With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.

Brookdale reported revenues of $813.2 million, up 3.7% year on year, falling short of analysts’ expectations by 1.7%. It was a softer quarter as it posted a significant miss of analysts’ EPS estimates and a miss of analysts’ revenue estimates.

Interestingly, the stock is up 15.9% since the results and currently trades at $10.56.

Read our full analysis of Brookdale’s results here.

Pediatrix Medical Group

With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states.

Pediatrix Medical Group reported revenues of $492.9 million, down 3.6% year on year. This result surpassed analysts’ expectations by 3.2%. Overall, it was a stunning quarter as it also produced an impressive beat of analysts’ same-store sales estimates and a beat of analysts’ EPS estimates.

The stock is up 32.9% since reporting and currently trades at $22.56.

Read our full, actionable report on Pediatrix Medical Group here, it’s free for active Edge members.

UnitedHealth

With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care.

UnitedHealth reported revenues of $113.2 billion, up 12.2% year on year. This print met analysts’ expectations. Taking a step back, it was a mixed quarter as it also logged a narrow beat of analysts’ customer base estimates but revenue in line with analysts’ estimates.

The company kept the number of customers flat at a total of 54.08 million. The stock is down 9.6% since reporting and currently trades at $330.25.

Read our full, actionable report on UnitedHealth here, it’s free for active Edge members.

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.62%

Investing.com

Radiopharm Theranostics Limited American Depositary Shares

Vision Marine Technologies

-8.84%

Disney

-1.94%

Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Consumer Goods, Technology and Basic Materials sectors led shares higher while losses in the Oil & Gas, Healthcare and Financials sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average lost 0.62%, while the S&P 500 index fell 0.24%, and the NASDAQ Composite index added 0.23%.

The best performers of the session on the Dow Jones Industrial Average were Walt Disney Company (NYSE:DIS), which rose 1.02% or 1.13 points to trade at 111.62 at the close. Meanwhile, NVIDIA Corporation (NASDAQ:NVDA) added 0.81% or 1.43 points to end at 177.72 and Boeing Co (NYSE:BA) was up 0.59% or 1.21 points to 206.71 in late trade.

The worst performers of the session were Johnson & Johnson (NYSE:JNJ), which fell 2.27% or 4.87 points to trade at 209.30 at the close. Chevron Corp (NYSE:CVX) declined 2.04% or 3.05 points to end at 146.75 and Unitedhealth Group (NYSE:UNH) was down 2.02% or 6.90 points to 334.20.

The top performers on the S&P 500 were Comcast Corp (NASDAQ:CMCSA) which rose 5.41% to 29.74, United Airlines Holdings Inc (NASDAQ:UAL) which was up 4.42% to settle at 112.46 and Estee Lauder Companies Inc (NYSE:EL) which gained 3.33% to close at 104.39.

The worst performers were Phillips 66 (NYSE:PSX) which was down 6.88% to 131.78 in late trade, Humana Inc (NYSE:HUM) which lost 6.03% to settle at 258.16 and The Mosaic Company (NYSE:MOS) which was down 5.65% to 23.46 at the close.

The top performers on the NASDAQ Composite were Intelligent Bio Solutions Inc (NASDAQ:INBS) which rose 900.00% to 5.50, Vision Marine Technologies Inc (NASDAQ:VMAR) which was up 155.72% to settle at 0.97 and AlphaVest Acquisition Corp (NASDAQ:AMCI) which gained 101.65% to close at 14.66.

The worst performers were Zynex Inc (NASDAQ:ZYXI) which was down 48.60% to 0.34 in late trade, Saverone 2014 Ltd ADR (NASDAQ:SVRE) which lost 46.89% to settle at 1.88 and Radiopharm Theranostics Ltd ADR (NASDAQ:RADX) which was down 43.65% to 5.99 at the close.

Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1745 to 989 and 101 ended unchanged; on the Nasdaq Stock Exchange, 1842 fell and 1519 advanced, while 176 ended unchanged.

Shares in United Airlines Holdings Inc (NASDAQ:UAL) rose to all time highs; rising 4.42% or 4.76 to 112.46. Shares in Intelligent Bio Solutions Inc (NASDAQ:INBS) rose to all time lows; gaining 900.00% or 4.95 to 5.50. Shares in Zynex Inc (NASDAQ:ZYXI) fell to 5-year lows; losing 48.60% or 0.32 to 0.34. Shares in Saverone 2014 Ltd ADR (NASDAQ:SVRE) fell to all time lows; losing 46.89% or 1.66 to 1.88.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was unchanged 0.00% to 16.50.

Gold Futures for February delivery was down 0.10% or 4.40 to $4,330.80 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February fell 2.89% or 1.64 to hit $55.03 a barrel, while the February Brent oil contract fell 2.87% or 1.74 to trade at $58.82 a barrel.

EUR/USD was unchanged 0.05% to 1.17, while USD/JPY fell 0.33% to 154.72.

The US Dollar Index Futures was down 0.10% at 97.86.

Risk Warnings and Disclaimers

Add to Favorites

Merck, Oracle among market cap stock movers on Tuesday

Investing.com

Thermo Fisher Scientific

-4.04%

Tuesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Oracle (ORCL) and Affirm Holdings (AFRM) are rallying, while stocks like Amkor Technology (AMKR) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200 billion USD and above)

Oracle (ORCL): +2.32%
Palantir Technologies Inc (PLTR): +2.05%
Johnson & Johnson (JNJ): -2.27%
Exxon Mobil (XOM): -2.34%
Thermo Fisher Scientific (TMO): -2.45%
United Health Group (UNH): -2.55%
Merck & Co (MRK): -2.62%
AbbVie Inc (ABBV): -2.25%
IBM (: -1.87%
Micron Technology (MU): -1.98%

Large-Cap Stock Movers ($10-$200 billion USD)

Amkor Technology (AMKR): -10.65%
Booz Allen Hamilton Holding Corp (BAH): -7.73%
Dillards (DDS): -6.53%
Humana Inc (HUM); Humana announces leadership transitions as insurance head to retire: -5.79%
Coupang LLC (CPNG): -5.96%
Lumentum Holdings Inc (LITE); Lumentum appoints onsemi CFO Thad Trent to board of directors: -5.14%
Circle Internet Group Inc (CRCL): +9.34%
dMY Technology Group III (; Jefferies initiates IonQ stock with Buy rating, sets $100 price target: +6.38%
Montes Archimedes Acquisition (ROIV): +5.23%
Affirm Holdings (AFRM): +11.36%

Mid-Cap Stock Movers ($2-$10 billion USD)

Navan Inc (NAVN): -14.6%
Frontier Group Holdings (ULCC); Frontier Airlines appoints James Dempsey as interim CEO: -14.15%
Destiny Tech100 (DXYZ): -12.01%
Thunder Bridge Capital Partners IV (CNCK): -12.0%
Arrowhead Research Corp (ARWR): -8.23%
Valspar Corp (VAL): -8.01%
Pbf Energy Inc (PBF): -9.22%
Corcept Therapeutics (CORT); Corcept Therapeutics stock initiated at Neutral by UBS with $95 target: -6.9%
Sezzle Inc PK (SEZL): +9.96%
Fermi America LLC (FRMI): +11.41%

Small-Cap Stock Movers ($300 million - $2 billion USD)

Armada Acquisition I (RZLV); Rezolve Ai expects to achieve positive adjusted EBITDA in December: +36.64%
Emerald Expositions Events Inc (EEX); Emerald Holding explores strategic options following acquisition inquiries: +38.42%
Tilray Inc (TLRY): +28.04%
NovaBay Pharmaceuticals Inc (NBY): +16.42%
Zenas Biopharma (ZBIO): +12.99%
Lightwave Logic Inc (LWLG); Lightwave Logic prices $35 million public offering of common stock: -20.82%
Jyong Biotech (MENS): -31.13%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Winners And Losers Of Q3: Elevance Health (NYSE:ELV) Vs The Rest Of The Health Insurance Providers Stocks

Stock Story

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the health insurance providers industry, including Elevance Health and its peers.

Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care.

The 12 health insurance providers stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 2.3% while next quarter’s revenue guidance was 1.1% below.

In light of this news, share prices of the companies have held steady as they are up 1.9% on average since the latest earnings results.

Elevance Health

Formerly known as Anthem until its 2022 rebranding, Elevance Health is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans.

Elevance Health reported revenues of $50.09 billion, up 12% year on year. This print exceeded analysts’ expectations by 1.2%. Overall, it was a strong quarter for the company with a beat of analysts’ EPS estimates and a narrow beat of analysts’ revenue estimates.

"Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we’re focused on advancing affordability and elevating the member experience through our growing value-based care partnerships and AI-enabled digital solutions that simplify access and improve outcomes. As we plan for 2026, we remain disciplined in managing what we can control – positioning our businesses for long-term, sustainable growth and value creation for all stakeholders.”

Interestingly, the stock is up 1.7% since reporting and currently trades at $360.

We think Elevance Health is a good business, but is it a buy today? Read our full report here, it’s free for active Edge members.

Best Q3: CVS Health

With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.

CVS Health reported revenues of $102.9 billion, up 7.8% year on year, outperforming analysts’ expectations by 4.1%. The business had an exceptional quarter with a solid beat of analysts’ same-store sales and revenue estimates.

The market seems unhappy with the results as the stock is down 2.9% since reporting. It currently trades at $79.79.

Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Molina Healthcare

Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.

Molina Healthcare reported revenues of $11.48 billion, up 11% year on year, exceeding analysts’ expectations by 4.6%. Still, it was a slower quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates.

Molina Healthcare delivered the weakest full-year guidance update in the group. The company lost 118,000 customers and ended up with a total of 5.63 million. As expected, the stock is down 13.6% since the results and currently trades at $168.08.

Read our full analysis of Molina Healthcare’s results here.

Cigna

With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans.

Cigna reported revenues of $69.57 billion, up 9.2% year on year. This print beat analysts’ expectations by 3.1%. Zooming out, it was a satisfactory quarter as it also produced an impressive beat of analysts’ revenue estimates but full-year EPS guidance in line with analysts’ estimates.

The company lost 3,000 customers and ended up with a total of 16.35 million. The stock is down 7.3% since reporting and currently trades at $277.36.

Read our full, actionable report on Cigna here, it’s free for active Edge members.

UnitedHealth

UnitedHealth reported revenues of $113.2 billion, up 12.2% year on year. This number was in line with analysts’ expectations. Taking a step back, it was a mixed quarter as it also logged a narrow beat of analysts’ customer base estimates but revenue in line with analysts’ estimates.

The company kept the number of customers flat at a total of 54.08 million. The stock is down 7% since reporting and currently trades at $339.75.

Read our full, actionable report on UnitedHealth here, it’s free for active Edge members.

Risk Warnings and Disclaimers

Add to Favorites

UnitedHealth Group Announces Earnings Release Date

Dow Jones Newswires

UnitedHealth

-2.67%

UnitedHealth Group will release its full year 2025 financial results and provide 2026 financial guidance on Tuesday, January 27, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company's website (www.unitedhealthgroup.com). The replay will be available through February 10 on the website.

About UnitedHealth Group

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251212897036/en/

CONTACT: Investors: investor_relations@uhg.com

Media: uhgmedia@uhg.com

Risk Warnings and Disclaimers

Add to Favorites

The Drug Market Is Being Redrawn. The Hidden Rules Still Apply. — Heard on the Street — WSJ

Dow Jones Newswires

By David Wainer

Imagine walking into a travel agency in the pre-internet days. You ask for a beachfront hotel on a Greek island. Two similar options fit: One is $250 a night, the other $350. But only the pricier one pays the agent a commission. Which one do you think they will steer you toward?

Thankfully, travel stopped working that way. Transparent online pricing exposed those incentives, forcing real competition.

Drug pricing, though, still resembles that old travel-agent model — only far more complex and opaque. The middleman here, the pharmacy-benefit manager, still earns money in ways that don't always align with what patients or employers want. And while transparency is finally creeping into the drug world, it is arriving slowly and with no guarantee it will meaningfully lower costs.

The core distortion is that pharmaceutical companies pay PBMs for access. Drugmakers pay hefty rebates — effectively kickbacks — to PBMs like CVS Health's Caremark and Cigna's Express Scripts. These help the drug companies secure preferred placement on insurance formularies, the list of covered drugs. That means the drug with the higher list price can be more attractive to a PBM if it delivers a bigger rebate.

Patients with deductibles or coinsurance then get hit with out-of-pocket costs tied to that inflated list price, while the rebate money flows back to insurers or employers to lower premiums for the broader pool. This system effectively punishes the sickest people.

That model is now under strain. Policymakers and the media have dragged PBMs into the spotlight. New federal rules in the Medicare and Medicaid programs removed pharma's incentives to increase list prices on some drugs. Discount cards and Mark Cuban's Cost Plus Drugs routinely sell the same medications for a fraction of what insurance charges. And a wave of more transparent PBMs is pulling away some corporate clients.

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the " gross-to-net bubble" — the vast gap, worth over $300 billion annually, between a drug's inflated list price and the real price that actually changes hands.

The most dramatic cracks are appearing in the weight-loss drug market. Because insurance coverage remains patchy, a growing cash-pay channel opened up there almost by accident. Eli Lilly and Novo Nordisk are now selling GLP-1 drugs directly to patients for a few hundred dollars a month. These same medicines once carried prices over $1,000 a month before PBM rebates.

The pressure is forcing the middlemen to respond in ways that look, at first glance, transformational. In October, Cigna said it would roll out a " rebate-free" pharmacy model for part of its business. The new approach will cut out the post-purchase rebate process by making the discounted price of the drug available upfront. That is good news for many patients, who will see lower out-of-pocket costs.

Cigna, which owns its own PBM, will automatically make this change for all the customers it fully insures in 2027. But companies that only use Cigna's PBM will be able to adopt it later on an optional basis, and many employers — who value rebates for helping offset premiums — might be slow to switch.

To some extent, UnitedHealth Group and CVS Health's PBM units have offered similar plans. But Adam Kautzner, president of Cigna's Evernorth Care Management and Express Scripts, says Cigna's model goes further. Under the traditional point-of-sale-rebate model offered by competitors, "legacy rebates still exist and are applied as an estimate at the counter," he notes. Under Cigna's new plan, people "instantly get discounts at the pharmacy counter, while drug companies get assurance upfront that their discounts are going straight to the patient."

The move is far from symbolic and won't be easy. Cigna's stock plunged after executives warned that the new model would require heavy investments that will squeeze margins in the near term.

Yet some of the incentives won't exactly change. That is because Cigna's PBM will continue to collect payments from drugmakers, just through different channels. The company has said nothing about changing the manufacturer fees that flow through Ascent, a Switzerland-based group-purchasing entity closely affiliated with its PBM. Those payments have quietly overtaken traditional rebates as the main driver of PBM profitability. They remain intact and largely invisible to employers.

Think of the shift this way: The travel agent stops taking a commission on the room rate but instead earns a "marketing fee" from the hotel. "In either model, pharma is still paying for preferential treatment in the formulary," notes Charles Rhyee, an analyst at TD Cowen.

Kautzner says "any retained fees will no longer be tied to the price of the medications to ensure our compensation is fully delinked from list prices set by drug companies." These fees are fully transparent to clients, he adds. Rhyee argues that the move is strategically smart: PBMs have become the political villain in the drug-pricing debate, often in ways he considers exaggerated given their margins tend to hover around 4%. Cigna is essentially betting it can stay ahead of regulators and competitors.

But PBMs will continue to face scrutiny, not simply because of how much money they make, but because of their opacity, which means employers and regulators can't easily tell whether they are getting good deals. AJ Loiacono, chief executive of Capital Rx — a fast-growing PBM with five million members — says that it is easier to find the cost of sending a satellite into orbit than the true price of a cholesterol drug. When the ultimate buyer can see what a drug really costs, efficiency follows, he says.

The big PBMs are now trying to pre-empt change before it is forced upon them. The question is whether incremental tweaks will be enough to preserve their market share and their bottom lines over the long term.

Write to David Wainer at david.wainer@wsj.com

Risk Warnings and Disclaimers

Add to Favorites

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 1.34%

Investing.com

Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Basic Materials, Financials and Industrials sectors led shares higher while losses in the Technology, Oil & Gas and Consumer Goods sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average gained 1.34% to hit a new all time high, while the S&P 500 index gained 0.21%, and the NASDAQ Composite index fell 0.26%.

The best performers of the session on the Dow Jones Industrial Average were Visa Inc Class A (NYSE:V), which rose 6.11% or 19.90 points to trade at 345.63 at the close. Meanwhile, Nike Inc (NYSE:NKE) added 2.96% or 1.95 points to end at 67.74 and Unitedhealth Group (NYSE:UNH) was up 2.57% or 8.44 points to 336.81 in late trade.

The worst performers of the session were Coca-Cola Co (NYSE:KO), which fell 1.57% or 1.10 points to trade at 69.11 at the close. NVIDIA Corporation (NASDAQ:NVDA) declined 1.55% or 2.85 points to end at 180.93 and Cisco Systems Inc (NASDAQ:CSCO) was down 1.22% or 0.98 points to 79.27.

The top performers on the S&P 500 were Royal Caribbean Cruises Ltd (NYSE:RCL) which rose 7.42% to 279.70, Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) which was up 6.81% to settle at 20.55 and Visa Inc Class A (NYSE:V) which gained 6.11% to close at 345.63.

The worst performers were Oracle Corporation (NYSE:ORCL) which was down 10.83% to 198.85 in late trade, Paramount Skydance Corp (NASDAQ:PSKY) which lost 4.08% to settle at 14.12 and International Flavors & Fragrances Inc (NYSE:IFF) which was down 3.28% to 63.25 at the close.

The top performers on the NASDAQ Composite were Agape ATP Corp (NASDAQ:ATPC) which rose 162.21% to 0.18, PetMed Express Inc (NASDAQ:PETS) which was up 68.36% to settle at 2.98 and Velo3D Inc (NASDAQ:VELO) which gained 55.58% to close at 13.38.

The worst performers were Oriental Culture Holding Ltd (NASDAQ:OCG) which was down 89.16% to 0.94 in late trade, Rezolute Inc (NASDAQ:RZLT) which lost 87.25% to settle at 1.39 and C3is Inc (NASDAQ:CISS) which was down 80.81% to 0.33 at the close.

Rising stocks outnumbered declining ones on the New York Stock Exchange by 1809 to 952 and 85 ended unchanged; on the Nasdaq Stock Exchange, 1837 rose and 1526 declined, while 175 ended unchanged.

Shares in Oriental Culture Holding Ltd (NASDAQ:OCG) fell to all time lows; down 89.16% or 7.76 to 0.94. Shares in Rezolute Inc (NASDAQ:RZLT) fell to 52-week lows; losing 87.25% or 9.55 to 1.39. Shares in C3is Inc (NASDAQ:CISS) fell to all time lows; down 80.81% or 1.39 to 0.33.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 5.20% to 14.95 a new 1-month low.

Gold Futures for February delivery was up 1.94% or 82.10 to $4,306.80 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January fell 0.99% or 0.58 to hit $57.88 a barrel, while the February Brent oil contract fell 1.06% or 0.66 to trade at $61.55 a barrel.

EUR/USD was unchanged 0.38% to 1.17, while USD/JPY fell 0.21% to 155.58.

The US Dollar Index Futures was down 0.45% at 97.98.

Risk Warnings and Disclaimers

Add to Favorites